Amphotericin B Injection
Injection
To Be Discontinued Active (discontinuing) — Day 279
FDA shortage record
- Substance
- Amphotericin B Injection
- Manufacturer
- Leadiant Biosciences, Inc.
- Dosage form
- Injection
- Presentation
- Abelcet, Injection, 5 mg/1 mL; 3.4 mg/1 mL; 1.5 mg/1 mL (NDC 57665-101-41)
- Therapeutic category
- Anti-Infective
- Package NDC
57665-101-41- Initially posted
- 08/08/2025
- Days on shortage list
- 279
- Discontinued
- 08/08/2025
- Current FDA status
- To Be Discontinued
- Shortage entries (current dataset)
- 1 record for Amphotericin B Injection
Why this shortage matters
Anti-infective drugs — antibiotics, antivirals, and antifungals — treat bacterial, viral, and fungal infections. A shortage can delay care for serious hospital-acquired or opportunistic infections, where drug choice and timing directly affect patient outcomes.
FDA therapeutic class: Anti-Infective
Reason and context
Discontinuation of the manufacture of the drug
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 800-447-0169.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.